Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV‐Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation
Identifieur interne : 000A81 ( Main/Exploration ); précédent : 000A80; suivant : 000A82Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV‐Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation
Auteurs : Kishor M. Kwara [États-Unis] ; Kishor M. Lartey [Ghana] ; Kishor M. Boamah [Ghana] ; Kishor M. Rezk [États-Unis] ; Kishor M. Oliver-Commey [Ghana] ; Kishor M. Kenu [Ghana] ; Kishor M. Kashuba [États-Unis] ; Kishor M. Court [États-Unis]Source :
- The Journal of Clinical Pharmacology [ 0091-2700 ] ; 2009-09.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Association de médicaments, Association médicamenteuse, Femelle, Foie (métabolisme), Ghana, Glucuronides (métabolisme), Glucuronosyltransferase (génétique), Humains, Infections opportunistes liées au SIDA (traitement médicamenteux), Infections à VIH (), Infections à VIH (traitement médicamenteux), Inhibiteurs de la transcriptase inverse (administration et posologie), Inhibiteurs de la transcriptase inverse (pharmacocinétique), Inhibiteurs de la transcriptase inverse (usage thérapeutique), Lamivudine (administration et posologie), Lamivudine (pharmacocinétique), Lamivudine (usage thérapeutique), Mâle, Médicaments génériques (pharmacocinétique), Médicaments génériques (usage thérapeutique), Polymorphisme génétique, Période, Stavudine (administration et posologie), Stavudine (pharmacocinétique), Stavudine (usage thérapeutique), Tuberculose (traitement médicamenteux), Tuberculose (étiologie), Zidovudine (administration et posologie), Zidovudine (pharmacocinétique), Zidovudine (usage thérapeutique).
- MESH :
- administration et posologie : Inhibiteurs de la transcriptase inverse, Lamivudine, Stavudine, Zidovudine.
- génétique : Glucuronosyltransferase.
- métabolisme : Foie, Glucuronides.
- pharmacocinétique : Inhibiteurs de la transcriptase inverse, Lamivudine, Médicaments génériques, Stavudine, Zidovudine.
- traitement médicamenteux : Infections opportunistes liées au SIDA, Infections à VIH, Tuberculose.
- usage thérapeutique : Inhibiteurs de la transcriptase inverse, Lamivudine, Médicaments génériques, Stavudine, Zidovudine.
- étiologie : Tuberculose.
- Adulte, Adulte d'âge moyen, Association de médicaments, Association médicamenteuse, Femelle, Ghana, Humains, Infections à VIH, Mâle, Polymorphisme génétique, Période.
- Wicri :
- geographic : Ghana.
English descriptors
- KwdEn :
- AIDS-Related Opportunistic Infections (drug therapy), Adult, Allele, Antimicrob agents chemother, Antiretroviral, Antiretroviral agents, Antiretroviral drugs, Assay, Body weight, Cell count, Chapel hill, Clearance, Clin, Clin pharmacokinet, Clin pharmacol, Clinical pharmacology, Cmax, Drug Combinations, Drug Therapy, Combination, Drug metab dispos, Drugs, Generic (pharmacokinetics), Drugs, Generic (therapeutic use), Efavirenz, Female, Generic, Generic nrtis, Genotype, Genotype frequencies, Ghana, Ghanaian, Ghanaian patients, Ghanaian patients table, Glucuronidation, Glucuronides (metabolism), Glucuronosyltransferase (genetics), HIV Infections (complications), HIV Infections (drug therapy), Half-Life, Human liver bank samples, Human liver microsomes, Humans, Immunodeficiency, Interindividual variability, Intracellular, Intracellular concentrations, Kwara, Lamivudine, Lamivudine (administration & dosage), Lamivudine (pharmacokinetics), Lamivudine (therapeutic use), Linear regression, Liver (metabolism), Liver bank samples, Liver samples, Livers zidovudine glucuronidation, Lower limit, Male, Middle Aged, Mrna, Mrna content, Noncarrier, Noncarrier carrier, Noncarriers, Nrti, Patients cmax, Peak concentration, Pharmacokinetic, Pharmacokinetic parameters, Pharmacokinetic testing, Pharmacokinetics, Pharmacol, Polymorphism, Polymorphism, Genetic, Possible effects, Protein content, Reverse Transcriptase Inhibitors (administration & dosage), Reverse Transcriptase Inhibitors (pharmacokinetics), Reverse Transcriptase Inhibitors (therapeutic use), Rifampin, Significant differences, Snp, Stavudine, Stavudine (administration & dosage), Stavudine (pharmacokinetics), Stavudine (therapeutic use), Tmax, Toxicity, Transcriptase inhibitors, Transporter, Tuberculosis (drug therapy), Tuberculosis (etiology), Zidovudine, Zidovudine (administration & dosage), Zidovudine (pharmacokinetics), Zidovudine (therapeutic use), Zidovudine clearance, Zidovudine glucuronidation, Zidovudine glucuronidation activity, Zidovudine metabolism, Zidovudine pharmacokinetic parameters, Zidovudine pharmacokinetics.
- MESH :
- chemical , administration & dosage : Lamivudine, Reverse Transcriptase Inhibitors, Stavudine, Zidovudine.
- chemical , genetics : Glucuronosyltransferase.
- chemical , metabolism : Glucuronides.
- chemical , pharmacokinetics : Drugs, Generic, Lamivudine, Reverse Transcriptase Inhibitors, Stavudine, Zidovudine.
- chemical , therapeutic use : Drugs, Generic, Lamivudine, Reverse Transcriptase Inhibitors, Stavudine, Zidovudine.
- geographic : Ghana.
- complications : HIV Infections.
- drug therapy : AIDS-Related Opportunistic Infections, HIV Infections, Tuberculosis.
- etiology : Tuberculosis.
- metabolism : Liver.
- Teeft :
- Adult, Allele, Antimicrob agents chemother, Antiretroviral, Antiretroviral agents, Antiretroviral drugs, Assay, Body weight, Cell count, Chapel hill, Clearance, Clin, Clin pharmacokinet, Clin pharmacol, Clinical pharmacology, Cmax, Drug Combinations, Drug Therapy, Combination, Drug metab dispos, Efavirenz, Female, Generic, Generic nrtis, Genotype, Genotype frequencies, Ghanaian, Ghanaian patients, Ghanaian patients table, Glucuronidation, Half-Life, Human liver bank samples, Human liver microsomes, Humans, Immunodeficiency, Interindividual variability, Intracellular, Intracellular concentrations, Kwara, Lamivudine, Linear regression, Liver bank samples, Liver samples, Livers zidovudine glucuronidation, Lower limit, Male, Middle Aged, Mrna, Mrna content, Noncarrier, Noncarrier carrier, Noncarriers, Nrti, Patients cmax, Peak concentration, Pharmacokinetic, Pharmacokinetic parameters, Pharmacokinetic testing, Pharmacokinetics, Pharmacol, Polymorphism, Polymorphism, Genetic, Possible effects, Protein content, Rifampin, Significant differences, Snp, Stavudine, Tmax, Toxicity, Transcriptase inhibitors, Transporter, Zidovudine, Zidovudine clearance, Zidovudine glucuronidation, Zidovudine glucuronidation activity, Zidovudine metabolism, Zidovudine pharmacokinetic parameters, Zidovudine pharmacokinetics.
Abstract
There are limited data on the pharmacokinetics of generic nucleoside reverse transcriptase inhibitors (NRTIs) in native African populations, in whom they are commonly used. The authors characterized the pharmacokinetics of lamivudine (n = 27), zidovudine (n = 16), and stavudine (n = 11) in human immunodeficiency virus (HIV)/tuberculosis (TB)‐coinfected Ghanaians and evaluated associations between zidovudine metabolism and UDP‐glucuronosyltransferase (UGT) 2B7 polymorphisms. Lamivudine, zidovudine, and stavudine apparent oral clearance (CL/F) values (mean ± SD [% coefficient of variation [CV]) were 7.3 ± 2.8 (39%), 31.9 ± 33.6 (106%), and 16.4 ± 5.8 (35%) mL/min/kg, respectively, whereas half‐life values were 4.2 ± 1.9 (46%), 8.1 ± 7.9 (98%), and 1.5 ± 1.0 (65%) hours, respectively. Zidovudine CL/F was 196% higher (P = .004) in UGT2B7*1c (c.735A>G) carriers versus noncarriers. This was confirmed using human liver bank samples (n = 52), which showed 48% higher (P = .020) zidovudine glucuronidation and 33% higher (P = .015) UGT2B7 protein inUGT2B 7*1c carriers versus noncarriers. In conclusion, generic NRTI pharmacokinetics in HIV/TB‐coinfected Ghanaians are similar to other populations, whereas the UGT2B7*1c polymorphism may explain in part relatively high interindividual variability in zidovudine clearance
Url:
- https://api.istex.fr/document/15A62A64732DE5905CD3D180C41C9182403ED5E1/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749505
DOI: 10.1177/0091270009338482
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000156
- to stream Istex, to step Curation: 000156
- to stream Istex, to step Checkpoint: 000217
- to stream Pmc, to step Corpus: 000237
- to stream Pmc, to step Curation: 000236
- to stream Pmc, to step Checkpoint: 000443
- to stream PubMed, to step Corpus: 000444
- to stream PubMed, to step Curation: 000444
- to stream PubMed, to step Checkpoint: 000444
- to stream Ncbi, to step Merge: 000338
- to stream Ncbi, to step Curation: 000338
- to stream Ncbi, to step Checkpoint: 000338
- to stream Main, to step Merge: 000A98
- to stream Main, to step Curation: 000A81
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV‐Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation</title>
<author><name sortKey="Kwara, Kishor M" sort="Kwara, Kishor M" uniqKey="Kwara K" first="Kishor M." last="Kwara">Kishor M. Kwara</name>
</author>
<author><name sortKey="Lartey, Kishor M" sort="Lartey, Kishor M" uniqKey="Lartey K" first="Kishor M." last="Lartey">Kishor M. Lartey</name>
</author>
<author><name sortKey="Boamah, Kishor M" sort="Boamah, Kishor M" uniqKey="Boamah K" first="Kishor M." last="Boamah">Kishor M. Boamah</name>
</author>
<author><name sortKey="Rezk, Kishor M" sort="Rezk, Kishor M" uniqKey="Rezk K" first="Kishor M." last="Rezk">Kishor M. Rezk</name>
</author>
<author><name sortKey="Oliver Ommey, Kishor M" sort="Oliver Ommey, Kishor M" uniqKey="Oliver Ommey K" first="Kishor M." last="Oliver-Commey">Kishor M. Oliver-Commey</name>
</author>
<author><name sortKey="Kenu, Kishor M" sort="Kenu, Kishor M" uniqKey="Kenu K" first="Kishor M." last="Kenu">Kishor M. Kenu</name>
</author>
<author><name sortKey="Kashuba, Kishor M" sort="Kashuba, Kishor M" uniqKey="Kashuba K" first="Kishor M." last="Kashuba">Kishor M. Kashuba</name>
</author>
<author><name sortKey="Court, Kishor M" sort="Court, Kishor M" uniqKey="Court K" first="Kishor M." last="Court">Kishor M. Court</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:15A62A64732DE5905CD3D180C41C9182403ED5E1</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1177/0091270009338482</idno>
<idno type="url">https://api.istex.fr/document/15A62A64732DE5905CD3D180C41C9182403ED5E1/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000156</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000156</idno>
<idno type="wicri:Area/Istex/Curation">000156</idno>
<idno type="wicri:Area/Istex/Checkpoint">000217</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000217</idno>
<idno type="wicri:doubleKey">0091-2700:2009:Kwara K:interindividual:variability:in</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749505</idno>
<idno type="RBID">PMC:2749505</idno>
<idno type="wicri:Area/Pmc/Corpus">000237</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000237</idno>
<idno type="wicri:Area/Pmc/Curation">000236</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000236</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000443</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000443</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000444</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000444</idno>
<idno type="wicri:Area/PubMed/Curation">000444</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000444</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000444</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000444</idno>
<idno type="wicri:Area/Ncbi/Merge">000338</idno>
<idno type="wicri:Area/Ncbi/Curation">000338</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000338</idno>
<idno type="wicri:doubleKey">0091-2700:2009:Kwara A:interindividual:variability:in</idno>
<idno type="wicri:Area/Main/Merge">000A98</idno>
<idno type="wicri:Area/Main/Curation">000A81</idno>
<idno type="wicri:Area/Main/Exploration">000A81</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV‐Coinfected Ghanaian Patients: <hi rend="italic">UGT2B7</hi>
*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation</title>
<author><name sortKey="Kwara, Kishor M" sort="Kwara, Kishor M" uniqKey="Kwara K" first="Kishor M." last="Kwara">Kishor M. Kwara</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Rhode Island</region>
</placeName>
<wicri:cityArea>Warren Alpert Medical School of Brown University, Providence</wicri:cityArea>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Lartey, Kishor M" sort="Lartey, Kishor M" uniqKey="Lartey K" first="Kishor M." last="Lartey">Kishor M. Lartey</name>
<affiliation wicri:level="3"><country xml:lang="fr">Ghana</country>
<wicri:regionArea>University of Ghana Medical School, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Boamah, Kishor M" sort="Boamah, Kishor M" uniqKey="Boamah K" first="Kishor M." last="Boamah">Kishor M. Boamah</name>
<affiliation wicri:level="3"><country xml:lang="fr">Ghana</country>
<wicri:regionArea>University of Ghana Medical School, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rezk, Kishor M" sort="Rezk, Kishor M" uniqKey="Rezk K" first="Kishor M." last="Rezk">Kishor M. Rezk</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>University of North Carolina at Chapel Hill, Chapel Hill</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Oliver Ommey, Kishor M" sort="Oliver Ommey, Kishor M" uniqKey="Oliver Ommey K" first="Kishor M." last="Oliver-Commey">Kishor M. Oliver-Commey</name>
<affiliation wicri:level="3"><country xml:lang="fr">Ghana</country>
<wicri:regionArea>Korle‐Bu Teaching Hospital, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kenu, Kishor M" sort="Kenu, Kishor M" uniqKey="Kenu K" first="Kishor M." last="Kenu">Kishor M. Kenu</name>
<affiliation wicri:level="3"><country xml:lang="fr">Ghana</country>
<wicri:regionArea>Korle‐Bu Teaching Hospital, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kashuba, Kishor M" sort="Kashuba, Kishor M" uniqKey="Kashuba K" first="Kishor M." last="Kashuba">Kishor M. Kashuba</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
<wicri:cityArea>University of North Carolina at Chapel Hill, Chapel Hill</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Court, Kishor M" sort="Court, Kishor M" uniqKey="Court K" first="Kishor M." last="Court">Kishor M. Court</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Tufts University School of Medicine, Boston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">The Journal of Clinical Pharmacology</title>
<title level="j" type="alt">JOURNAL OF CLINICAL PHARMACOLOGY</title>
<idno type="ISSN">0091-2700</idno>
<idno type="eISSN">1552-4604</idno>
<imprint><biblScope unit="vol">49</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1079">1079</biblScope>
<biblScope unit="page" to="1090">1090</biblScope>
<biblScope unit="page-count">12</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2009-09">2009-09</date>
</imprint>
<idno type="ISSN">0091-2700</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0091-2700</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS-Related Opportunistic Infections (drug therapy)</term>
<term>Adult</term>
<term>Allele</term>
<term>Antimicrob agents chemother</term>
<term>Antiretroviral</term>
<term>Antiretroviral agents</term>
<term>Antiretroviral drugs</term>
<term>Assay</term>
<term>Body weight</term>
<term>Cell count</term>
<term>Chapel hill</term>
<term>Clearance</term>
<term>Clin</term>
<term>Clin pharmacokinet</term>
<term>Clin pharmacol</term>
<term>Clinical pharmacology</term>
<term>Cmax</term>
<term>Drug Combinations</term>
<term>Drug Therapy, Combination</term>
<term>Drug metab dispos</term>
<term>Drugs, Generic (pharmacokinetics)</term>
<term>Drugs, Generic (therapeutic use)</term>
<term>Efavirenz</term>
<term>Female</term>
<term>Generic</term>
<term>Generic nrtis</term>
<term>Genotype</term>
<term>Genotype frequencies</term>
<term>Ghana</term>
<term>Ghanaian</term>
<term>Ghanaian patients</term>
<term>Ghanaian patients table</term>
<term>Glucuronidation</term>
<term>Glucuronides (metabolism)</term>
<term>Glucuronosyltransferase (genetics)</term>
<term>HIV Infections (complications)</term>
<term>HIV Infections (drug therapy)</term>
<term>Half-Life</term>
<term>Human liver bank samples</term>
<term>Human liver microsomes</term>
<term>Humans</term>
<term>Immunodeficiency</term>
<term>Interindividual variability</term>
<term>Intracellular</term>
<term>Intracellular concentrations</term>
<term>Kwara</term>
<term>Lamivudine</term>
<term>Lamivudine (administration & dosage)</term>
<term>Lamivudine (pharmacokinetics)</term>
<term>Lamivudine (therapeutic use)</term>
<term>Linear regression</term>
<term>Liver (metabolism)</term>
<term>Liver bank samples</term>
<term>Liver samples</term>
<term>Livers zidovudine glucuronidation</term>
<term>Lower limit</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mrna</term>
<term>Mrna content</term>
<term>Noncarrier</term>
<term>Noncarrier carrier</term>
<term>Noncarriers</term>
<term>Nrti</term>
<term>Patients cmax</term>
<term>Peak concentration</term>
<term>Pharmacokinetic</term>
<term>Pharmacokinetic parameters</term>
<term>Pharmacokinetic testing</term>
<term>Pharmacokinetics</term>
<term>Pharmacol</term>
<term>Polymorphism</term>
<term>Polymorphism, Genetic</term>
<term>Possible effects</term>
<term>Protein content</term>
<term>Reverse Transcriptase Inhibitors (administration & dosage)</term>
<term>Reverse Transcriptase Inhibitors (pharmacokinetics)</term>
<term>Reverse Transcriptase Inhibitors (therapeutic use)</term>
<term>Rifampin</term>
<term>Significant differences</term>
<term>Snp</term>
<term>Stavudine</term>
<term>Stavudine (administration & dosage)</term>
<term>Stavudine (pharmacokinetics)</term>
<term>Stavudine (therapeutic use)</term>
<term>Tmax</term>
<term>Toxicity</term>
<term>Transcriptase inhibitors</term>
<term>Transporter</term>
<term>Tuberculosis (drug therapy)</term>
<term>Tuberculosis (etiology)</term>
<term>Zidovudine</term>
<term>Zidovudine (administration & dosage)</term>
<term>Zidovudine (pharmacokinetics)</term>
<term>Zidovudine (therapeutic use)</term>
<term>Zidovudine clearance</term>
<term>Zidovudine glucuronidation</term>
<term>Zidovudine glucuronidation activity</term>
<term>Zidovudine metabolism</term>
<term>Zidovudine pharmacokinetic parameters</term>
<term>Zidovudine pharmacokinetics</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Association de médicaments</term>
<term>Association médicamenteuse</term>
<term>Femelle</term>
<term>Foie (métabolisme)</term>
<term>Ghana</term>
<term>Glucuronides (métabolisme)</term>
<term>Glucuronosyltransferase (génétique)</term>
<term>Humains</term>
<term>Infections opportunistes liées au SIDA (traitement médicamenteux)</term>
<term>Infections à VIH ()</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Inhibiteurs de la transcriptase inverse (administration et posologie)</term>
<term>Inhibiteurs de la transcriptase inverse (pharmacocinétique)</term>
<term>Inhibiteurs de la transcriptase inverse (usage thérapeutique)</term>
<term>Lamivudine (administration et posologie)</term>
<term>Lamivudine (pharmacocinétique)</term>
<term>Lamivudine (usage thérapeutique)</term>
<term>Mâle</term>
<term>Médicaments génériques (pharmacocinétique)</term>
<term>Médicaments génériques (usage thérapeutique)</term>
<term>Polymorphisme génétique</term>
<term>Période</term>
<term>Stavudine (administration et posologie)</term>
<term>Stavudine (pharmacocinétique)</term>
<term>Stavudine (usage thérapeutique)</term>
<term>Tuberculose (traitement médicamenteux)</term>
<term>Tuberculose (étiologie)</term>
<term>Zidovudine (administration et posologie)</term>
<term>Zidovudine (pharmacocinétique)</term>
<term>Zidovudine (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Lamivudine</term>
<term>Reverse Transcriptase Inhibitors</term>
<term>Stavudine</term>
<term>Zidovudine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Glucuronosyltransferase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Glucuronides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Drugs, Generic</term>
<term>Lamivudine</term>
<term>Reverse Transcriptase Inhibitors</term>
<term>Stavudine</term>
<term>Zidovudine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Drugs, Generic</term>
<term>Lamivudine</term>
<term>Reverse Transcriptase Inhibitors</term>
<term>Stavudine</term>
<term>Zidovudine</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Inhibiteurs de la transcriptase inverse</term>
<term>Lamivudine</term>
<term>Stavudine</term>
<term>Zidovudine</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term>
<term>HIV Infections</term>
<term>Tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glucuronosyltransferase</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Liver</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Foie</term>
<term>Glucuronides</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Inhibiteurs de la transcriptase inverse</term>
<term>Lamivudine</term>
<term>Médicaments génériques</term>
<term>Stavudine</term>
<term>Zidovudine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections opportunistes liées au SIDA</term>
<term>Infections à VIH</term>
<term>Tuberculose</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de la transcriptase inverse</term>
<term>Lamivudine</term>
<term>Médicaments génériques</term>
<term>Stavudine</term>
<term>Zidovudine</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Tuberculose</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adult</term>
<term>Allele</term>
<term>Antimicrob agents chemother</term>
<term>Antiretroviral</term>
<term>Antiretroviral agents</term>
<term>Antiretroviral drugs</term>
<term>Assay</term>
<term>Body weight</term>
<term>Cell count</term>
<term>Chapel hill</term>
<term>Clearance</term>
<term>Clin</term>
<term>Clin pharmacokinet</term>
<term>Clin pharmacol</term>
<term>Clinical pharmacology</term>
<term>Cmax</term>
<term>Drug Combinations</term>
<term>Drug Therapy, Combination</term>
<term>Drug metab dispos</term>
<term>Efavirenz</term>
<term>Female</term>
<term>Generic</term>
<term>Generic nrtis</term>
<term>Genotype</term>
<term>Genotype frequencies</term>
<term>Ghanaian</term>
<term>Ghanaian patients</term>
<term>Ghanaian patients table</term>
<term>Glucuronidation</term>
<term>Half-Life</term>
<term>Human liver bank samples</term>
<term>Human liver microsomes</term>
<term>Humans</term>
<term>Immunodeficiency</term>
<term>Interindividual variability</term>
<term>Intracellular</term>
<term>Intracellular concentrations</term>
<term>Kwara</term>
<term>Lamivudine</term>
<term>Linear regression</term>
<term>Liver bank samples</term>
<term>Liver samples</term>
<term>Livers zidovudine glucuronidation</term>
<term>Lower limit</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mrna</term>
<term>Mrna content</term>
<term>Noncarrier</term>
<term>Noncarrier carrier</term>
<term>Noncarriers</term>
<term>Nrti</term>
<term>Patients cmax</term>
<term>Peak concentration</term>
<term>Pharmacokinetic</term>
<term>Pharmacokinetic parameters</term>
<term>Pharmacokinetic testing</term>
<term>Pharmacokinetics</term>
<term>Pharmacol</term>
<term>Polymorphism</term>
<term>Polymorphism, Genetic</term>
<term>Possible effects</term>
<term>Protein content</term>
<term>Rifampin</term>
<term>Significant differences</term>
<term>Snp</term>
<term>Stavudine</term>
<term>Tmax</term>
<term>Toxicity</term>
<term>Transcriptase inhibitors</term>
<term>Transporter</term>
<term>Zidovudine</term>
<term>Zidovudine clearance</term>
<term>Zidovudine glucuronidation</term>
<term>Zidovudine glucuronidation activity</term>
<term>Zidovudine metabolism</term>
<term>Zidovudine pharmacokinetic parameters</term>
<term>Zidovudine pharmacokinetics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Association de médicaments</term>
<term>Association médicamenteuse</term>
<term>Femelle</term>
<term>Ghana</term>
<term>Humains</term>
<term>Infections à VIH</term>
<term>Mâle</term>
<term>Polymorphisme génétique</term>
<term>Période</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There are limited data on the pharmacokinetics of generic nucleoside reverse transcriptase inhibitors (NRTIs) in native African populations, in whom they are commonly used. The authors characterized the pharmacokinetics of lamivudine (n = 27), zidovudine (n = 16), and stavudine (n = 11) in human immunodeficiency virus (HIV)/tuberculosis (TB)‐coinfected Ghanaians and evaluated associations between zidovudine metabolism and UDP‐glucuronosyltransferase (UGT) 2B7 polymorphisms. Lamivudine, zidovudine, and stavudine apparent oral clearance (CL/F) values (mean ± SD [% coefficient of variation [CV]) were 7.3 ± 2.8 (39%), 31.9 ± 33.6 (106%), and 16.4 ± 5.8 (35%) mL/min/kg, respectively, whereas half‐life values were 4.2 ± 1.9 (46%), 8.1 ± 7.9 (98%), and 1.5 ± 1.0 (65%) hours, respectively. Zidovudine CL/F was 196% higher (P = .004) in UGT2B7*1c (c.735A>G) carriers versus noncarriers. This was confirmed using human liver bank samples (n = 52), which showed 48% higher (P = .020) zidovudine glucuronidation and 33% higher (P = .015) UGT2B7 protein inUGT2B 7*1c carriers versus noncarriers. In conclusion, generic NRTI pharmacokinetics in HIV/TB‐coinfected Ghanaians are similar to other populations, whereas the UGT2B7*1c polymorphism may explain in part relatively high interindividual variability in zidovudine clearance</div>
</front>
</TEI>
<affiliations><list><country><li>Ghana</li>
<li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>Massachusetts</li>
<li>Rhode Island</li>
<li>Région du Grand Accra</li>
</region>
<settlement><li>Accra</li>
</settlement>
</list>
<tree><country name="États-Unis"><region name="Rhode Island"><name sortKey="Kwara, Kishor M" sort="Kwara, Kishor M" uniqKey="Kwara K" first="Kishor M." last="Kwara">Kishor M. Kwara</name>
</region>
<name sortKey="Court, Kishor M" sort="Court, Kishor M" uniqKey="Court K" first="Kishor M." last="Court">Kishor M. Court</name>
<name sortKey="Kashuba, Kishor M" sort="Kashuba, Kishor M" uniqKey="Kashuba K" first="Kishor M." last="Kashuba">Kishor M. Kashuba</name>
<name sortKey="Rezk, Kishor M" sort="Rezk, Kishor M" uniqKey="Rezk K" first="Kishor M." last="Rezk">Kishor M. Rezk</name>
</country>
<country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Lartey, Kishor M" sort="Lartey, Kishor M" uniqKey="Lartey K" first="Kishor M." last="Lartey">Kishor M. Lartey</name>
</region>
<name sortKey="Boamah, Kishor M" sort="Boamah, Kishor M" uniqKey="Boamah K" first="Kishor M." last="Boamah">Kishor M. Boamah</name>
<name sortKey="Kenu, Kishor M" sort="Kenu, Kishor M" uniqKey="Kenu K" first="Kishor M." last="Kenu">Kishor M. Kenu</name>
<name sortKey="Oliver Ommey, Kishor M" sort="Oliver Ommey, Kishor M" uniqKey="Oliver Ommey K" first="Kishor M." last="Oliver-Commey">Kishor M. Oliver-Commey</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A81 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A81 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaGhanaV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:15A62A64732DE5905CD3D180C41C9182403ED5E1 |texte= Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV‐Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation }}
This area was generated with Dilib version V0.6.31. |